A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...

Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of ...

AstraZeneca and Daiichi Sankyo's TROP2-targeting drug Datroway has been approved by the European Commission for some previously untreated patients with metastatic triple-negative breast cancer (TNBC), ...

The patient access system isn't broken because people wanted it to fail. It's broken because it was built for an era where the phone and fax machine were the only universal interfaces, and business ...

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

The once-daily, oral TEC/JAK3 inhibitor has shown efficacy in active and stable nonsegmental vitiligo (NSV) – the most common form of the disease – in which the most common form of vitiligo, ...

Anti-OX40L antibody amlitelimab was discarded as a treatment for atopic dermatitis last week, and today – during its ...

A dual GLP-1 and glucagon agonist developed by Altimmune has been shown to reduce drinking in people with alcohol use ...

A US judge has ordered that Novo Nordisk must face some allegations in court that it defrauded investors by making misleading ...

According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...

AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, the first market for the hair loss ...

Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...